Breaking News

miRecule, GBI Biomanufacturing Enter Strategic ARC Therapies Pact

GBI will support miRecule in the development and clinical production of its Antibody-RNA Conjugate therapies.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

miRecule, a biotechnology company developing RNA therapies, and GBI Biomanufacturing, a CDMO, entered a strategic partnership to advance the development and clinical supply of miRecule’s Antibody-RNA Conjugate (ARC) based products. Under the agreement, GBI will support miRecule in the development and clinical production of its ARC therapies. These therapies combine the precision of antibody targeting with the efficacy of oligonucleotide-based therapeutics, representing an advancement in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters